Test | Author |  Op. | Year | Country (no. of studies in MA) | Train. | n | Prev (%) | Age | Criterion standard | Sn. in % (95% CI) | Sp. in % (95% CI) | LR+ (95% CI) | LR− (95% CI) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Diffuse interstitial syndrome in heart failure | Martindale et al. [55] | EP | 2016 | MA (8) | NR | 1914 | 48 | NR | Final diagnosis | 85.3 (82.8–87.5) | 92.7 (90.9–94.3) | 7.4 (4.2–12.8) | 0.16 (0.05–0.51) |
McGivery et al. [56] | EP | 2018 | MA (5)c | NR | 1387 | NR | NR | Final diagnosis | 88.6 (79.6–94.0) | 83.2 (63.2–93.5) | 5.27a | 0.14a | |
Lian et al. [57] | EPd | 2018 | MA (15) | NR | 3309 | NR | NR | Final diagnosis | 85 (84–87) | 91 (89–92) | 8.94 (5.64–14.18) | 0.14 (0.08–0.26) | |
Koh et al. [75] | EP | 2018 | Singapore | 20 h. | 231 | 36 | 68 | Final diagnosis | 71.4 (60.5–80.8) | 80.9 (72.5–87.6) | 3.73 (2.50–5.57) | 0.35 (0.25–0.50) | |
Maw et al. [58] | EPd | 2019 | MA (6) | NR | 1827 | 20–62 | NR | Final diagnosis or echoc./BNP | 88 (75–95) | 90 (88–92) | 8.63 (6.93–10.74) | 0.14 (0.06–0.29) | |
Staub et al. [59] | EPd | 2019 | MA (14) | NR | 2778 | 24–88 | NR | Final diagnosis | NR (75–90)b | NR (80–90)b | NR | NR | |
Pivetta et al. [60] | EP | 2019 | Italy | 40 x | 518 | 43 | 79 | Final diagnosis | 93.5 (87.7–97.2) | 95.5 (90.5–98.3) | 20.9 (9.54–45.7) | 0.07 (0.03–0.13) | |
Bekgoz et al. [76] | EP | 2019 | Turkey | 2 h. | 383 | 22 | 66 | Final diagnosis | 87 (79–93) | 97 (94–98) | 29a | 0.13a | |
Pneumonia (adults) | Ye et al. [63] | EP | 2015 | MA (5) | NR | 742 | – | NR | Final diagnosis | 95 (93–97) | 90 (86–94) | 9.5a | 0.056a |
Orso et al. [62] | EP | 2018 | MA (17) | NR | 5108 | NR | 67 | Final diagnosis or CXR and/or CCT | 92 (87–96) | 93 (86–97) | 13a | 0,086a | |
Staub et al. [59] | EPd | 2019 | MA (14) | NR | 1896 | 30–85 | NR | Final diagnosis or CXR and/or CCT | NR (85–95)b | NR (75–90)b | NR | NR | |
Amatya et al. [64] | EP | 2018 | Nepal | 1 h. | 62 | 71 | 59 | CCT | 91 (78–97)a | 61 (36–83)a | 2.34 (1.30–4.20)a | 0.15 (0.05–0.41)a | |
Koh et al. [75] | EP | 2018 | Singapore | 20 h. | 231 | 21 | 68 | Final diagnosis | 65.3 (50.4–78.3) | 82.0 (74.9–87.8) | 3.63 (2.44–5.40) | 0.42 (0.29–0.63) | |
Bekgoz et al. [76] | EP | 2019 | Turkey | 2 h. | 383 | 24 | 66 | Final diagnosis | 82 (78–89) | 98 (97–99) | 41a | 0.18a | |
Pneumonia (children) | Copetti and Cattarossi [65] | EP | 2008 | Italy | NR | 79 | 76 | 5 | CXR, CT or final diagnosis | 100a | 100a | ∞a | 0a |
Shah et al. [66] | EP | 2013 | USA | 1 h. | 200 | 18 | 3 | CXR | 86 (71–94) | 89 (83–93) | 7.8 (5.0–12.4) | 0.2 (0.1–0.4) | |
Pneumothorax | Ebrahimi et al. [70] | EP | 2014 | MA (14)c | – | 1803 | NR | NR | CCT | 88 (82–94) | 99 (98–100) | 88a | 0.12a |
Staub et al. [71] | EPd | 2018 | MA (13) | – | 2378 | 14 | NR | CXR, CCT or chest tube (with rush of air) | 81 (71–88) | 98 (97–99) | 67.9 (26.3–148) | 0.18 (0.11–0.29) | |
Riccardi et al. [72] | EP | 2019 | Italy | – | 190 | 9 | 59 | CXR and/or CCT | 94 | 100 | ∞a | 0.06a | |
Bekgoz et al. [76] | EP | 2019 | Turkey | 2 h. | 383 | 2 | 66 | Final diagnosis | 85 | 100 | ∞a | 0.15a | |
COPD/Asthma | Koh et al. [75] | EP | 2018 | Singapore | 20 h. | 231 | 27 | 68 | Final diagnosis | 64.5 (51.3–76.3) | 89.8 (83.4–94.3) | 6.31 (3.72–10.72) | 0.40 (0.28–0.56) |
Bekgoz et al. [76] | EP | 2019 | Turkey | 2 h. | 383 | 28 | 66 | Final diagnosis | 96 (90–97) | 75 (70–80) | 3.8a | 0.05a |